Cost‐effectiveness of carbon ion radiation therapy for locally recurrent rectal cancer

Publisher Website
Google Scholar
Abstract
The aim of this study was to evaluate the cost‐effectiveness of carbon ion radiotherapy compared with conventional multimodality therapy in the treatment of patients with locally recurrent rectal cancer. Direct costs for diagnosis, recurrent treatment, follow‐up, visits, supportive therapy, complications, and admission were computed for each individual using a sample of 25 patients presenting with local recurrent rectal cancer at the National Institute of Radiological Science (NIRS) and Gunma University Hospital (GUH). Patients received only radical surgery for primary rectal adenocarcinoma and had isolated unresectable pelvic recurrence. Fourteen and 11 patients receiving treatment for the local recurrence between 2003 and 2005 were followed retrospectively at NIRS and GUH, respectively. Treatment was carried out with carbon ion radiotherapy (CIRT) alone at NIRS, while multimodality therapy including three‐dimensional conformal radiotherapy, chemotherapy, and hyperthermia was performed at GUH. The 2‐year overall survival rate was 85% and 55% for CIRT and multimodality treatment, respectively. The mean cost was ¥4 803 946 for the CIRT group and ¥4 611 100 for the multimodality treatment group. The incremental cost‐effectiveness ratio for CIRT was ¥6428 per 1% increase in survival. The median duration of total hospitalization was 37 days for CIRT and 66 days for the multimodality treatment group. In conclusion, by calculating all direct costs, CIRT was found to be a potential cost effective treatment modality as compared to multimodality treatment for locally recurrent rectal cancer. (Cancer Sci 2010)